1
Esau Christine, Lollo Bridget, Bennett C Frank, Freier Susan M, Griffey Richard H, Baker Brenda F, Vickers Timothy, Marcusson Eric G, Koller Erich, Swayze Eric E, Jain Ravi, Bhat Balkrishen, Peralta Eigen: Oligomeric compounds and compositions for use in modulation of small non-coding rnas. Isis Pharmaceuticals, Esau Christine, Lollo Bridget, Bennett C Frank, Freier Susan M, Griffey Richard H, Baker Brenda F, Vickers Timothy, Marcusson Eric G, Koller Erich, Swayze Eric E, Jain Ravi, Bhat Balkrishen, Peralta Eigen, LEGAARD Paul K, February 17, 2005: WO/2005/013901 (110 worldwide citation)

Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targ ...


2
Bennett C Frank, Dean Nicholas M, Kole Ryszard, Kopczynski Casey C: Chimeric oligomeric compounds for modulation of splicing. Isis Pharmaceuticals, Bennett C Frank, Dean Nicholas M, Ercole Biotech, Kole Ryszard, Kopczynski Casey C, FULLER Michael L, March 8, 2007: WO/2007/028065 (74 worldwide citation)

Disclosed herein are compounds, compositions and methods for modulating splicing of a selected target mRNA. Further provided are uses of the disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Methods of enhancing cellular uptake, modulati ...


3
Griffey Richard H, Bennett C Frank, Ecker David J, Ward Donna T, Freier Susan M: Microrna as ligands and target molecules. Isis Pharmaceuticals, Griffey Richard H, Bennett C Frank, Ecker David J, Ward Donna T, Freier Susan M, LEGAARD Paul K, March 17, 2005: WO/2005/023986 (17 worldwide citation)

The present invention provides methods for the identification of target molecules that bind to ligands, particularly microRNA ligands and mimics thereof and/or microRNA target molecules and mimics thereof, with as little as milliniolar (mM) affinity using mass spectrometry. The methods may be used t ...


4
BENNETT C FRANK: Compositions and methods for modulation of smn2 splicing in a subject. Isis Pharmaceuticals, Pauling David C, December 23, 2010: WO/2010/148249 (13 worldwide citation)

Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.


5
Bennett C Frank, Chajut Ayelet, Esau Christine, Marcusson Eric G, Yerushalmi Noga: Targeting micrornas for the treatment of liver cancer. Isis Pharmaceuticals, Rosetta Genomics, Bennett C Frank, Chajut Ayelet, Esau Christine, Marcusson Eric G, Yerushalmi Noga, PUTKEY Frances R, May 7, 2009: WO/2009/058907 (12 worldwide citation)

Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such co ...


6
Bhanot Sanjay, Dobie Kenneth W, Freier Susan M, Dean Nicholas M, Bennett C Frank: Modulation of glucocorticoid receptor expression. Isis Pharmaceuticals, Bhanot Sanjay, Dobie Kenneth W, Freier Susan M, Dean Nicholas M, Bennett C Frank, BAK Mary E, August 4, 2005: WO/2005/071080 (11 worldwide citation)

Compounds, compositions and methods are provided for modulating the expression of glucocorticoid receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucocorticoid receptor. Methods of using these compounds for modulation of glucocorticoid receptor expression and ...


7
Bennett C Frank, Rothlein Robert, Kishimoto Takashi Kei, Cowsert Lex M: Antisense modulation of calreticulin expression. Isis Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Bennett C Frank, Rothlein Robert, Kishimoto Takashi Kei, Cowsert Lex M, LICATA Jane Massey, September 6, 2002: WO/2002/068688 (9 worldwide citation)

Antisense compounds, compositions and methods are provided for modulating the expression of calreticulin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding calreticulin. Methods of using these compounds for modulation of calret ...


8
RIGO Frank, BENNETT C Frank, KRAINER Adrian R, HUA Yimin: Composés et procédés pour moduler linteraction entre des protéines et des acides nucléiques cibles, Compounds and methods for modulating interaction between proteins and target nucleic acids. Isis Pharmaceuticals, Cold Spring Harbor Laboratory, RIGO Frank, BENNETT C Frank, KRAINER Adrian R, HUA Yimin, FORD Clifford E, December 22, 2011: WO/2011/159836 (8 worldwide citation)

Provided herein are antisense compounds and methods for recruiting one or more non-cleaving protein to a target nucleic acid in a cell. In certain instances such recruitment of a non-cleaving protein alters the function or activity of the target nucleic acid. In certain such instances, the target nu ...


9
Bennett C Frank, Dobie Kenneth W, Freier Susan M, Crooke Stanley T: Compositions and methods for modulation of lmna expression. Isis Pharmaceuticals, Bennett C Frank, Dobie Kenneth W, Freier Susan M, Crooke Stanley T, FULLER Michael L, April 26, 2007: WO/2007/047913 (8 worldwide citation)

Disclosed herein are compounds, compositions and methods for modulating the expression of LMNA in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and ...


10
BENNETT C Frank: Modulation de larn de rétention nucléaire, Modulation of nuclear-retained rna. Isis Pharmaceuticals, BENNETT C Frank, PAULING David C, January 26, 2012: WO/2012/012467 (7 worldwide citation)

Provided herein are methods, compounds, and compositions for reducing expression of a nrRNA in an animal. Also provided herein are methods, compounds, and compositions for treating, ameliorating, delaying or reducing a symptom of a disease or disorder associated with a nuclear-retained RNA in an ani ...